Page 20 - 80_02

Development
of
anti-­-Leishmania
vaccines…

18
Duthie,
M.
S.;
Raman,
V.
S.;
Piazza,
F.
M.;
Reed,
S.
G.
The
development
and
clinical

evaluation
of
second-­-generation
leishmaniasis
vaccines.
Vaccine
30,
134-­-141
(2012).

19
Singh,
B.;
Sundar,
S.
Leishmaniasis:
Vaccine
candidates
and
perspectives.
Vaccine
30,

3834-­-3842
(2012).

20
Raman,
V.
S.;
Duthie,
M.
S.;
Fox,
C.
B.;
Matlashewski,
G.;
Reed,
S.
G.
Adjuvants
for
Leishmania

vaccines:
from
models
to
clinical
application.
Frontiers
in
Immunology
3,
144
(2012).

21
Kedzierski,
L.
Leishmaniasis.
Human
Vaccines
7,
1204-­-1214
(2011).

22
Okwor,
I.;
Mou,
Z.;
Liu,
D.;
Uzonna,
J.
Protective
immunity
and
vaccination
against

cutaneous
leishmaniasis.
Frontiers
in
Immunology
3,
128
(2012).

23
McConville,
M.
J.;
Blackwell,
J.
M.
Developmental
changes
in
the
glycosylated

phosphatidylinositols
of
Leishmania
donovani.
Characterization
of
the
promastigote
and

amastigote
glycolipids.
Jornal
of
Biological
Chemistry
266,
15170-­-15179
(1991).

24
Pimenta,
P.
F.;
Saraiva,
E.
M.;
Sacks,
D.
L.
The
comparative
fine
structure
and
surface

glycoconjugate
expression
of
three
life
stages
of
Leishmania
major.
Experimental

Parasitology
72,
191-­-204
(1991).

25
Shreffler,
W.
G.;
Burns,
J.
M.
Jr.;
Badaro,
R.;
Ghalib,
H.
W.;
Button,
L.
L.;
McMaster,
W.
R.;

Reed,
S.
G.
Antibody
responses
of
visceral
leishmaniasis
patients
to
gp63,
a
major
surface

glycoprotein
of
Leishmania
species.
The
Journal
of
Infectious
Diseases
167,
426-­-430

(1993).

26
Morales,
G.;
Carrillo,
G.;
Requena,
J.
M.;
Guzman,
F.;
Gomez,
L.
C.;
Patarroyo,
M.
E.;
Alonso,
C.

Mapping
of
the
antigenic
determinants
of
the
Leishmania
infantum
gp63
protein

recognized
by
antibodies
elicited
during
canine
visceral
leishmaniasis.
Parasitology
114,

507-­-516
(1997).

27
Soto,
M.;
Ramirez,
L.;
Pineda,
M.
A.;
Gonzalez,
V.
M.;
Entringer,
P.
F.;
Indiani
de
Oliveira,
C.;

Nascimento,
I.
P.;
Souza,
A.
P.;
Corvo,
L.;
Alonso,
C.;
Brodskyn,
C.;
Barral,
A.;
Barral-­-Netto,

M.;
Iborra,
S.
Searching
genes
encoding
Leishmania
antigens
for
diagnosis
and
protection.

Scholarly
Research
Exchange
2009,
ID
173039
(2009).

28
Cote-­-Sierra,
J.;
Bredan,
A.;
Toldos,
C.
M.;
Stijlemans,
B.;
Brys,
L.;
Cornelis,
P.;
Segovia,
M.;
de

Baetselier,
P.;
Revets,
H.
Bacterial
lipoprotein-­-based
vaccines
induce
tumor
necrosis

factor-­-dependent
type
1
protective
immunity
against
Leishmania
major.
Infection
and

Immunity
70,
240-­-248
(2002).

29
Yang,
D.
M.;
Rogers,
M.
V.;
Liew,
F.
Y.
Identification
and
characterization
of
host-­-protective

T-­-cell
epitopes
of
a
major
surface
glycoprotein
(gp63)
from
Leishmania
major.

Immunology
72,
3-­-9
(1991).

30
Rivas,
L.;
Kahl,
L.;
Manson,
K.;
McMahon-­-Pratt,
D.
Biochemical
characterization
of
the

protective
membrane
glycoprotein
GP46/M-­-2
of
Leishmania
amazonensis.
Molecular
and

Biochemical
Parasitology
47,
235-­-243
(1991).

31
Boceta,
C.;
Alonso,
C.;
Jimenez-­-Ruiz,
A.
Leucine
rich
repeats
are
the
main
epitopes
in

Leishmania
infantum
PSA
during
canine
and
human
visceral
leishmaniasis.
Parasite

Immunology
22,
55-­-62
(2000).

32
Berberich,
C.;
Requena,
J.
M.;
Alonso,
C.
Cloning
of
genes
and
expression
and
antigenicity

analysis
of
the
Leishmania
infantum
KMP-­-11
protein.
Experimental
Parasitology
85,
105-­-
108
(1997).

33
Ramirez,
J.
R.;
Berberich,
C.;
Jaramillo,
A.;
Alonso,
C.;
Velez,
I.
V.
Molecular
and
antigenic

characterization
of
the
Leishmania
(Viannia)
panamensis
kinetoplastid
membrane
protein-­-
11.
Memorias
do
Instituto
Oswaldo
Cruz.
93,
247-­-254
(1998).

34
Passos,
S.;
Carvalho,
L.
P.;
Orge,
G.;
Jeronimo,
S.
M.;
Bezerra,
G.;
Soto,
M.;
Alonso,
C.;

Carvalho,
E.
M.
Recombinant
Leishmania
antigens
for
serodiagnosis
of
visceral

leishmaniasis.
Clinical
and
Diagnostic
Laboratory
Immunolology
12,
1164-­-1167
(2005).

35
Carvalho,
L.
P.;
Passos,
S.;
Dutra,
W.
O.;
Soto,
M.;
Alonso,
C.;
Gollob,
K.
J.;
Carvalho,
E.
M.;

Ribeiro
de
Jesus,
A.
Effect
of
LACK
and
KMP11
on
IFN-­-gamma
production
by
peripheral

blood
mononuclear
cells
from
cutaneous
and
mucosal
leishmaniasis
patients.

Scandinavian
Journal
of
Immunology
61,
337-­-342
(2005).

36
Carrillo,
E.;
Crusat,
M.;
Nieto,
J.;
Chicharro,
C.;
Thomas
M,
C.;
Martinez,
E.;
Valladares,
B.;

Cañavate,
C.;
Requena,
J.
M.;
Lopez,
M.
C.;
Alvar,
J.;
Moreno,
J.
Immunogenicity
of
HSP-­-70,

KMP-­-11
and
PFR-­-2
leishmanial
antigens
in
the
experimental
model
of
canine
visceral

leishmaniasis.
Vaccine
26,
1902-­-1911
(2008).

37
Basu,
R.;
Bhaumik,
S.;
Basu,
J.
M.;
Naskar,
K.;
De,
T.;
Roy,
S.
Kinetoplastid
membrane

protein-­-11
DNA
vaccination
induces
complete
protection
against
both
pentavalent

259